Drug to treat prostate cancer is expected to produce a major windfall for two pharma makers.
Formulary Watch
Latest News
All News
Advertisement
FDA approved yet another indication for pembrolizumab (Keytruda) to treat patients with recurrent, locally advanced or metastatic, squamous cell carcinoma of the esophagus (ESCC).
FDA is adding an important new Boxed Warning on the higher-dose version of this drug.
FDA approved the first and only ready-to-use insulin for IV infusion in hospitals and acute care settings.
Patients with overactive bladder taking this OAB drug did not experience an excess risk of CV events compared with other treatments.
Asthma patients may soon treat themselves with first-ever digital maintenance inhaler.
While some are concerned that President Trump’s proposed “favored nations” policy would harm pharma makers, one analyst is not as concerned.
While some are concerned that President Trump’s proposed “favored nations” policy would harm pharma makers, one analyst is not as concerned.
EpiPens have been in short supply, but stakeholders are trying to fill in the access gap.
FDA warns opioid repackers for "significant violations."
Advertisement
FDA granted Fast Track designation to a popular diabetes drug to reduce the risk of cardiovascular death and hospitalization for heart failure in people with chronic heart failure.
The validity of a new large study linking anticholinergic drugs to the risk of dementia has stirred up controversy.
FDA recalls insulin pumps due to cybersecurity miscommunication.
A women’s health organization is concerned about the safety and effectiveness of bremelanotide (Vyleesi) after FDA approved it to treat hypoactive sexual desire disorder (HSDD) in premenopausal women.
A new report from OptumRx reveals the top 4 drugs in development for the second quarter of 2019.
The first FDA-approved device to reduce functional abdominal pain in younger patients with irritable bowel syndrome is now available to medical providers.
A record number of new oncology treatments launched in the US last year and spending on cancer drugs soared. Here are the top 6 cancer drug trends revealed in the report.
FDA cleared the first-and-only calcitonin gene-related peptide (CGRP) antibody for cluster headaches.
The first respiratory biologic to be approved for administration via an autoinjector will be available in the US soon.
FDA cleared alpelisib (Piqray), the first PI3K inhibitor to treat breast cancer, to be used in combination with fulvestrant (Faslodex).
FDA granted market authorization for a non-invasive, smartphone device that offers respite from migraines.
Express Scripts, a Cigna company, plans to launch the industry's first stand-alone digital health formulary.
FDA approved some important new therapies, including the first anticoagulant for children, an injectable for diabetic retinopathy, and a treatment for renal cell carcinoma.
Generic drug makers are defending their practices after 44 US states accused Teva Pharmaceuticals and other pharma makers of conspiring to inflate their prices in a lawsuit.
A new government rule requiring pharma makers to disclose drug prices in television ads will likely create more confusion for consumers, analysts and organizations said.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
National Alliance survey shows employers are leaving the ‘big 3’ for other PBMs
2
7 takeaways from the MHE webinar on PBM reform and transparency
3
Novo Nordisk's ziltivekimab falls short to reduce cardiovascular events in phase 3 trial
4
Prior authorization isn’t shrinking. Its savings are
5